Do the results of your analysis make the case for existing Neuren shareholders to consider also taking a position in Acadia now, because (subject to the risks of the acquiror being a different entity), Acadia is the likely suitor, and NNZ-2591 would not be subject to anyone’s consent rights post acquisition, which would increase the value of NNZ-2591?
Ann: Q2 2023 quarterly activity and cash flow report, page-61
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.86 |
Change
0.640(3.17%) |
Mkt cap ! $2.666B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $21.10 | $20.39 | $9.299M | 447.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 671 | $20.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.86 | 262 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |